COLUMBUS, Ohio, Aug. 31, 2016 /PRNewswire/ -- ProclaRx, a biopharmaceutical company developing innovative therapeutics for patients suffering from serious bacterial infections, is pleased to announce the appointment of Dinar Dhond to its Board of Directors. Dhond joins ProclaRx's Board of Directors with over 30 years of professional experience in the healthcare and pharmaceutical industries. This new board member appointment comes on the heels of the company's recent hiring of its Chief Operating Officer, Doug Martin.
"I am thrilled to welcome Dinar as a board member to our Board of Directors, which includes a stellar lineup of business, technology, and scientific industry leaders," said Nick Henderson, Chairman of the Board, ProclaRx. "Dinar brings a wealth of knowledge and influence in his respective fields and will be a tremendous asset to our team as we continue to further our mission of eliminating bacterial biofilms in order to help cure chronic diseases. We look forward to his guidance and insights toward the further success of ProclaRx."
Dhond currently serves as President of Nexus Informatics and is a founding member of Clinical Consulting Services, LLC, which includes Nexus Informatics, a software development company focused on developing patient access programs for specialty drugs; CSSi LifeSciences™, a trusted partner from discovery to commercialization for developing drugs and devices; and CSSi, the global leader in patient recruitment, enrollment, and retention solutions for the clinical research industry. Over the years, Dhond has held several senior level positions with companies such as Pharmaceutical Research Plus, Inc., Oracle Corporation, and HealthSTAR Communications, Inc. Dhond has gained extensive knowledge and experience in application architecture, software development, and solutions development. Dhond holds a B.S. degree in Computer Science and an M.B.A from Loyola University Maryland.
"I am very grateful for the opportunity to serve on the Board of Directors of this rapidly evolving biotech company, which is dedicated to improving the treatment of patients with advanced bacterial infections," said Dhond. "Recurrent infections and antibiotic resistance are major public health and clinical problems, and ProclaRx hopes to one day eliminate these issues through the use of its antibody technology. As one of the company's biggest advocates, I look forward to furthering ProclaRx's commitment to developing innovative therapeutics and getting their potentially game-changing technologies to market in a timely and cost-effective manner."
To learn more about ProclaRx and its innovative anti-biofilm technology, please visit www.proclarx.com.
ProclaRx is a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections. ProclaRx has a breakthrough discovery that inhibits and prevents bacterial biofilms. Lead indications include advanced wound care, chronic suppurative otitis media, and CVID sinusitis. Visit www.proclarx.com, call 949-302-2165, or email [email protected].
Public Relations & Marketing Coordinator